Caribou Biosciences, Inc. Share Price & Technical Analysis
CRBU · $2.10 (+5.53%)
Healthcare / Biotechnology
$2.10
+5.53%
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD1…
Price chart
Seasonality
May has 4 positive and 1 negative years (last 5 years shown)
11% return in May, 1% avg return in past 3 year May month.
39% return in 2026, -7% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -12% | 36% | 6% | 0% | 11% | – | – | – | – | – | – | – | 39% |
| 25 | -12% | -14% | -18% | 0% | 22% | 18% | 54% | -5% | 21% | 4% | -44% | -16% | 10% |
| 24 | 7% | 27% | -36% | -29% | -22% | -16% | 35% | -4% | -9% | 0% | 10% | -27% | -64% |
| 23 | 13% | -15% | -13% | -19% | 2% | -5% | 71% | -18% | -20% | -25% | 64% | -2% | 34% |
| 22 | -29% | -8% | -4% | -20% | 12% | -36% | 47% | 22% | 8% | -10% | -6% | -34% | -57% |
Monthly return % by calendar month · historical pattern, not a forecast
Neutral · Strong · Uptrend
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$201.83M
P/E ratio
—
52W high
$3.54
52W low
$0.96
Volume
13,96,555
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Caribou Biosciences, Inc. share price today?
- Caribou Biosciences, Inc. (CRBU) last traded around $2.10 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does CRBU have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for CRBU. Download the app for real-time alerts.
- How can I analyze Caribou Biosciences, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.